Andreas Josefsson1, Anna Linder1, Despina Flondell Site2, Giacomo Canesin2, Anna Stiehm2, Aseem Anand2, Anders Bjartell2,3, Jan-Erik Damber1, Karin Welén1. 1. Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 2. Department of Urology, Division of Urological Cancers, Skåne University Hospital, Lund University, Lund, Sweden. 3. Department of Translational Medicine, Division of Urological Cancers, Skåne University Hospital, Lund University, Lund, Sweden.
Abstract
BACKGROUND: Analysis of circulating tumor cells (CTC) is a promising prognostic marker in castration-resistant prostate cancer (CRPC). The aim of this study was to investigate CTC detection and phenotyping as prognostic biomarkers for response to primary androgen deprivation therapy (ADT) of metastatic prostate cancer (PC). METHODS: PC patients presenting with a prostate specific antigen (PSA) >80 ng/ml and/or metastatic disease, intended for ADT were enrolled in the study. CTCs were analysed for expression of PSA prostate specific membrane antigen (PSMA) and epidermal growth factor receptor (EGFR) before and three months after ADT and related to progression. RESULTS: At inclusion, 46 out of 53 patients (87%) were CTC-positive with a sensitivity and specificity for distant metastases (M1) of 98% and 75%, respectively. In patients with M1-disease, EGFR-detection in CTC was an independent prognostic marker for progression-free survival, whereas PSA and alkaline phosphatase serum levels, Gleason score, or T-stage were not. EGFR-positive patients had significantly shorter time to progression (5 months) compared to EGFR-negative patients (11 months) (P < 0.05). CONCLUSIONS: In this explorative study, CTCs were detected in 98% of M1 patients and detection of EGFR in CTCs was strongly associated with poor outcome, which indicated that phenotypical analysis of CTC could be a promising prognostic marker of ADT-response in castration-naïve metastatic PC patients. Prostate 77:849-858, 2017.
BACKGROUND: Analysis of circulating tumor cells (CTC) is a promising prognostic marker in castration-resistant prostate cancer (CRPC). The aim of this study was to investigate CTC detection and phenotyping as prognostic biomarkers for response to primary androgen deprivation therapy (ADT) of metastatic prostate cancer (PC). METHODS: PC patients presenting with a prostate specific antigen (PSA) >80 ng/ml and/or metastatic disease, intended for ADT were enrolled in the study. CTCs were analysed for expression of PSA prostate specific membrane antigen (PSMA) and epidermal growth factor receptor (EGFR) before and three months after ADT and related to progression. RESULTS: At inclusion, 46 out of 53 patients (87%) were CTC-positive with a sensitivity and specificity for distant metastases (M1) of 98% and 75%, respectively. In patients with M1-disease, EGFR-detection in CTC was an independent prognostic marker for progression-free survival, whereas PSA and alkaline phosphatase serum levels, Gleason score, or T-stage were not. EGFR-positive patients had significantly shorter time to progression (5 months) compared to EGFR-negative patients (11 months) (P < 0.05). CONCLUSIONS: In this explorative study, CTCs were detected in 98% of M1 patients and detection of EGFR in CTCs was strongly associated with poor outcome, which indicated that phenotypical analysis of CTC could be a promising prognostic marker of ADT-response in castration-naïve metastatic PC patients. Prostate 77:849-858, 2017.
Authors: Esther Campos-Fernández; Letícia S Barcelos; Aline Gomes de Souza; Luiz R Goulart; Vivian Alonso-Goulart Journal: Am J Cancer Res Date: 2019-07-01 Impact factor: 6.166
Authors: Karen A Autio; Robert Dreicer; Justine Anderson; Jorge A Garcia; Ajjai Alva; Lowell L Hart; Matthew I Milowsky; Edwin M Posadas; Charles J Ryan; Ryon P Graf; Ryan Dittamore; Nicole A Schreiber; Jason M Summa; Hagop Youssoufian; Michael J Morris; Howard I Scher Journal: JAMA Oncol Date: 2018-10-01 Impact factor: 31.777
Authors: Heather H Cheng; Melissa Plets; Hongli Li; Celestia S Higano; Catherine M Tangen; Neeraj Agarwal; Nicholas J Vogelzang; Maha Hussain; Ian M Thompson; Muneesh Tewari; Evan Y Yu Journal: Prostate Date: 2017-11-06 Impact factor: 4.104
Authors: Andreas Josefsson; Karin Larsson; Marianne Månsson; Jens Björkman; Eva Rohlova; Daniel Åhs; Helena Brisby; Jan-Erik Damber; Karin Welén Journal: Oncotarget Date: 2018-06-29